Intercept Pharmaceuticals (ICPT) Files $75M IPO

September 4, 2012 3:38 PM EDT
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering price is $75 million. The company plans to list on the Nasdaq Global Market under the ticker "ICPT."

The offering is being made through BofA Merrill Lynch, BMO Capital Markets, Needham & Company, Wedbush PacGrow, and Life Sciences.

Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver disease utilizing our expertise in bile acid chemistry.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities

Merrill Lynch, Needham & Company, Bank of America, BMO Capital

Add Your Comment